Total
0
Shares
Image sourced from CNBC Television
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Regenerative medicine company AVITA Medical (AVH) will focus on its burns division in 2020 using its RECELL system
  • RECELL is a spray product that allows healthcare professionals to produce a suspension of Spray-On Skin Cells using a small sample of the patient’s own skin
  • AVITA’s goal to expand RECELL to 25 new burns centres is well underway
  • Two new clinics have already ordered the technology
  • The company reported its revenue has doubled to $13,530 within the year
  • It is also aiming to advance treatments for trauma and soft tissue injuries
  • Similar to the burn market, surgeons treat these injuries by grafting skin to repair defects from accidents
  • AVITA is up 1.23 per cent on the market today, trading at 82.5¢ per share

Regenerative medicine company AVITA Medical (AVH) has updated the market on its half-year report.

AVITA’s lead product, RECELL System, is used around the globe to treat a variety of skin defects.

The spray product allows healthcare professionals to produce a suspension of Spray-On Skin Cells using a small sample of the patient’s own skin.

This suspension contains the cells necessary to regenerate the outer layer of natural, healthy skin and is prepared and applied at the point-of-care in as little as 30 minutes.

RECELL’s revenue has doubled within the year to hit $13,530, compared to $6,929 this time last year.

AVITA said the U.S. RECELL System is off to a pleasing start in 2020. It made an appearance at the National Sales Meeting (NSM) this month and spend a significant time consulting the burns surgeons.

Burns

The company is focusing on the burns division throughout the 2020 calendar year.

“We continue to be pleased with early RECELL System utilization as we progress our “go deep” strategy within the in-patient burn setting,” CEO Mike Perry said.

“We are focused on driving incremental growth within existing accounts, together with broadening our commercial footprint via the addition of 25 burns centres throughout calendar 2020,” he added.

AVITA’s goal of expanding RECELL to 25 new burns centres is well underway as two new centres have already ordered the technology.

“Early 2020 sales performance has highlighted the commitment of burn specialists to the RECELL System, particularly among our group of super users,” Mike told the market.

In the U.S., AVITA says there is a $2 billion potential market opportunity.

Soft Tissue

It is also aiming to advance the trauma and soft tissue injuries where similar to burn market, surgeons graft skin to repair defects from accidents (e.g. degloving, lacerations, gunshots, etc).

In September 2019, the company secured an investigational device exemption (IDE) to pursue FDA approval for soft tissue reconstruction. This study will treat 65 trauma patients using RECELL.

AVITA is up 1.23 per cent on the market today, trading at 82.5¢ per share at 12:15 pm AEDT.

AVH by the numbers
More From The Market Herald
Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke

" Alcidion (ASX:ALC) to raise $55m & acquire Silverlink

Alcidion (ALC) has announced plans to raise $55 million and buy patient software specialists, Silverlink PCS Software.
Actinogen Medical (ASX:ACW) - CEO & Managing Director, Dr Steven Gourlay

" Actinogen Medical (ASX:ACW) partners with Oxford University

Actinogen (ACW) has announced a collaboration with Oxford University researchers to investigate Xanamem and a condition called mild autonomous cortisol secretion (MACS).
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) soars on ‘positive’ Rett syndrome trial results

Neuren Pharmaceuticals’ (NEU) shares have soared following positive top-line results from a phase three study on Rett syndrome.

" Recce Pharmaceuticals (ASX:RCE) spikes amid trial update

Shares in Recce Pharmaceuticals (RCE) have spiked amid a positive update in the clinical trial for the treatment of burn wound infections.